Post Reply
5661-5680 of 10899
Gem become stone !!
Stone become sand !!!
Sand become dust !!!
Dust become ????
XiaoMaGe888 ( Date: 18-Sep-2008 09:37) Posted:
|
Now is best time to !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Shortists traders should also stop being smug about being part of the 10% that makes money from the remaining 90%. Even ML and LB are going down due to debts. They were once the Super BBs. Shorting is essentially a process to try and make money from debt - borrow shares and sell. Debt is not what it used to be; its no longer acceptable now. I wonder if there will be new regulations to prohibit these kinds of debt given the current climate. I really hope there will be.
All the long term holders should just stop lending their shares. How much do you guys earn from lending it out? Compare that to the loss in value of holdings. Some people say, if its long term holders, its alright. Well, if the purchase price is 70c and the target is $2.10, that's a 200% increase. But now the price is 45.5c. That's >350% increase to reach $2.10. Given also the base being built at the lower price, there's also stronger inertia against going up to hit that high target price.
Bengster, since you are a substantial holder, are you also lending out your shares? Why don't you use your contacts to convince everyone to stop doing it? At the very least, it will stop the bleeding and it will also cause an upwards rationalisation of the prices as shortists need to buy back to return all the borrowed shares.
bengster68 ( Date: 17-Sep-2008 12:34) Posted:
|
money is king,,,,,,,,,,,,,,,,now,,,,,,,,,,,,when tomorow history low pijia,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,jus like ferrochina
Abbott & Boston Scientific: Rising Stent Stars (CNBC)
Veteran medical device analyst Mike Weinstein at JPMorgan is out with a pretty remarkable research note about the fast-changing market for drug-coated stents.
Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging. The devices were plagued by safety concerns regarding blood clots forming several months or years after they were put in.
There are now four players in the space and Weinstein is telling clients that the latest entrant, the Xiences stent from Abbott, is quickly emerging as the dominant product. Boston Scientific sells the exact same stent, but under the brand name Promus. Weinstein says that Xience/Promus are already approaching 50 percent market share. "The speed of the shift is fascinating to watch, as cardiologists who just a few months ago were telling us that they would initially use Xience in only a quarter of their procedures are now apparently making it their lead product," he writes.
Medtronic won approval earlier this year of its drug-coated stent Endeavor. And BSX and Johnson & Johnson sell the older products Taxus and Cypher, respectively.
Studies show Xience/Promus work better and may be safer than the other stents and doctors apparently think the new products are easier to insert than the older ones.
Weinstein says, "Boston's (Scientific) marketing of Promus...has turned out to be much more aggressive than expected. The result has been higher Promus uptake, higher Xience uptake, and a rapid drop-off for the existing products."
But Weinstein points out that BSX could be a victim of its own success because it buys the new stents from ABT and then slaps the Promus name on them. "Boston's challenge is that it may not have enough Promus to continue to grow its share within the market. Under the Abbott agreement," he writes, "Boston (Scientific) must forecast and pre-order its supply for each six month period with 3 months of the supply fixed and 3 months variable. Boston can increase its order monthly, but each month there are caps on how much it can raise its order." Interesting.
New Drug-Coated Stent
Exceeds Abbott's Views
Abbott Laboratories' Xience drug-coated stent is exceeding the company's expectations following its introduction in the U.S. in early July, Abbott's chief financial officer said.
"We are rapidly gaining market share," said Thomas C. Freyman during a Bank of America conference. Abbott's products compete against devices made by Boston Scientific Corp., Medtronic Inc. and Johnson & Johnson.
"We expect to be the market-share leader by the end of the year...........
*** BIG's older Everolimus DES technology will be the market leader in USA within 6 months after launch. Why is Biomatrix still stuck at FDA IDA after LEADERS results? Americans are denying themselves from the best DES.
Hi D.T.B, couple of weeks back BIG presented the LEADERS results against JNJ. The trial was meant to prove "non-inferiority" which Biomatrix achieved all the objectives. However, the 9 months data superiority was not powerful enough to show statistical P-value superiority. I have summarised some of the key end point measurements of LEADERS (BIG's Biomatrix VS JNJ's Cypher) and ENDEAVORIII (Medtronic's Endeavor VS JNJ's Cypher).
Although this results has brought a lot of international recognition for BIG, somehow the share price still cannot perform. Jialat.
bengster68 ( Date: 02-Sep-2008 01:32) Posted:
|
allright ( Date: 17-Sep-2008 10:06) Posted:
|
U.S. District Court Judge Sue Robinson ordered Boston Scientific and Medtronic to pay J&J's Cordis unit damages originally awarded in 2000, plus interest, for infringement of Cordis' original Palmaz balloon expandable stent patent, J&J said.
When the patent infringement cases were originally tried in 2000, Cordis received jury verdicts of $324 million against Boston Scientific and $271 million against Medtronic.
After a series of rulings and appeals, both cases were retried in March 2005, with Cordis again prevailing.
"We are very pleased that Judge Robinson granted our motion for reinstatement of damages and gratified that this litigation finally appears to be drawing to a close," said Seth Fischer, company group chairman for the Cordis franchise.
Stents are tiny wire-mesh tubes inserted into diseased coronary to prop them open after they have been surgically cleared of blockages.
"We have been awaiting this ruling for some time, and we took a charge for a portion of this judgment in the third quarter of FY08," a Medtronic spokesman said. "We are also now reviewing the details of the judgment before determining any further steps."
A spokesman for Boston Scientific did not immediately have a comment.
allright ( Date: 17-Sep-2008 09:09) Posted:
|
bengster68 ( Date: 17-Sep-2008 01:23) Posted:
|
Who are they paying to? Who owns the patents?
--+ Boston Scientific Drops Most in Two Months After Patent Ruling 2008-09-16 19:52:44.480 GMT By Alex Nussbaum Sept. 16 (Bloomberg) -- Boston Scientific Corp. fell the most in almost two months in New York trading, a day after a U.S. judge ordered the medical device maker to pay $324 million in a patent infringement case involving its heart stents. The company fell 96 cents, or 7.3 percent, to $12.24 at 3:42 p.m. in composite New York Stock Exchange trading, after earlier declining 9.8 percent, its biggest plunge since July 22. The Natick, Massachusetts-based company had gained 13.5 percent this year prior to today. For Related News: For health stories from the U.S.: TNI US HEA BN
Fewer deaths with drug stents than bare metal: study
CHICAGO (Reuters) - Drug-coated stents implanted into clogged heart arteries are associated with a significantly lower risk of death than bare-metal versions, researchers at the Cleveland Clinic said on Monday.
Use of stents coated with drugs to prevent scar tissue from reclogging arteries cleared of plaque has fallen as much as 50 percent in recent years due to concerns the tiny wire-mesh tubes can cause blood clots long after they are implanted.
However, recent data have suggested drug-coated stents may be as safe as uncoated versions and may actually help lower the risk of heart attack or death.
Researchers at the Cleveland Clinic found a 38 percent reduction in the risk of death from all causes in patients who received drug-eluting stents.
"This study and the preponderance of the evidence support the notion that the overall risk of stent thrombosis (clots) with DES does not translate into higher mortality in these patients," the researchers concluded in the Journal of the American College of Cardiology.
The study looked at data from a registry of 8,036 patients who underwent stent procedures at the hospital between March 2003 and June 2007.
The rate of death during 4 1/2 years of follow-up was 8 percent for patients treated with drug-coated stents and 17 percent for those who received bare-metal stents.
Even when adjusted for factors such as socioeconomic status, cancer, renal failure and anemia, the link between drug-eluting stent treatment and lower mortality persisted, the researchers said.
While the reason for the decrease in mortality seen with drug-eluting stents is unknown, a reduction in heart attacks and death due to reclogging of the arteries may play a substantial role, the researchers said.
Patients implanted with drug-eluting stents also received anti-clotting drugs for longer periods of time, which could also explain the lower mortality rates, they said.
Johnson & Johnson and Boston Scientific Corp were the sole makers of drug-eluting stents for the United States until Medtronic Inc and Abbott Laboratories entered the market this year.
jackjames ( Date: 14-Sep-2008 11:26) Posted:
|
give bengster68 a break.. It's okay that he loves this stock.. nothing wrong...
In fact, he gives all the solid information eventhough we know nuts about this industry.